<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> affects approximately one quarter of population in developed countries </plain></SENT>
<SENT sid="1" pm="."><plain>Its presence is a major risk for development of both type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> is 2-3 times higher in individuals with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> than in age-matched controls </plain></SENT>
<SENT sid="3" pm="."><plain>Most important components of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> with or without <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo>, atherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, prothrombotic state and proinflammatory state </plain></SENT>
<SENT sid="4" pm="."><plain>Early identification of subjects with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is very important, since they represent a target group for multiple lifestyle and pharmacological interventions </plain></SENT>
<SENT sid="5" pm="."><plain>Lifestyle interventions, antiobesity drugs and drugs increasing insulin sensitivity prevented development of T2DM in subjects with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> in randomized trials </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment of atherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> to the therapeutic goals defined for diabetic patients seems reasonable and both <z:chebi fb="0" ids="35664">statins</z:chebi> and fibrates could be used based on evidence from clinical trials </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment of <z:hpo ids='HP_0000822'>hypertension</z:hpo> should also aim for target levels similar to those in diabetic patients </plain></SENT>
<SENT sid="8" pm="."><plain>Using drugs affecting renin-<z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> axis, as first choice seems reasonable based on evidence from clinical trials showing the ability of these drugs to prevent T2DM and decrease <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
</text></document>